Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00077454 · ClinicalTrials.gov registry record · Phase 1
Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 95
- Enrollment target
NCT00077454: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00077454 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 95 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00077454, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 95 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of erlotinib when given with temozolomide in treating young patients with recurrent or refractory solid tumors. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving erlotinib with temozolomide may kill more tumor cells.
Interventions
- OTHER laboratory biomarker analysis
- DRUG temozolomide
- OTHER pharmacological study
- DRUG erlotinib hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2004-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00077454
The ClinicalTrials.gov registry entry for NCT00077454 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00077454 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00077454 about?
NCT00077454 is a clinical study titled "Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors". This phase I trial is studying the side effects and best dose of erlotinib when given with temozolomide in treating young patients with recurrent or refractory solid tumors. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, s...
What is the current status of trial NCT00077454?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 95 participants. The study started on 2004-02.
What interventions are being tested in trial NCT00077454?
The interventions under investigation include: laboratory biomarker analysis (OTHER), temozolomide (DRUG), pharmacological study (OTHER), erlotinib hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00077454?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.